|Effect of Recombinant Adenovirus-p53 Combined With Radiotherapy on Long-Term Prognosis of Advanced Nasopharyngeal Carcinoma|
|Pan, Jian-ji1; Zhang, Shan-wen1; Chen, Chuan-beng1; Xiao, Shao-wen1; Sun, Yan1; Liu, Chang-qin1; Su, Xing1; Li, Dong-ming1; Xu, Gang1; Xu, Bo1; Lu, You-yong1|
|刊名||JOURNAL OF CLINICAL ONCOLOGY|
|WOS标题词||Science & Technology|
|关键词[WOS]||WILD-TYPE P53 ; SQUAMOUS-CELL CARCINOMA ; GENE-TRANSFER ; LUNG-CANCER ; IN-VIVO ; THERAPY ; EXPRESSION ; HEAD ; ANGIOGENESIS ; MUTATIONS|
To centrally assess the safety, efficacy, and 6-year follow-up of recombinant adenovirus-p53 (rAd-p53) combined with radiotherapy (RT) for patients with nasopharyngeal carcinoma (NPC).
Patients and Methods
A randomized controlled clinical study on rAd-p53 combined with RT in 42 patients with NPC was compared with a control group of 40 patients with NPC treated with RT alone. In the group receiving rAd-p53 combined with RT, rAd-p53 was intratumorally injected once a week for 8 weeks. Concurrent RT (70 Gy in 35 fractions) was given to the nasopharyngeal tumor and neck lymph node. Patients and tumors were monitored for adverse events and responses.
rAd-p53-specific p53 mRNA was detected in postinjection of rAd-p53 biopsies from 16 (94.1%) of 17 patients. Upregulation of p21/WAF1 and Bax and downregulation of vascular endothelial growth factor were observed in postinjection tumor biopsy. Complete response rate in the group receiving rAd-p53 combined with RT was observed at 2.73 times that of the group receiving RT alone (66.7% v 24.4%). Six-year follow-up data showed that rAd-p53 significantly increased the 5-year locoregional tumor control rate by 25.3% for patients with NPC treated with irradiation (P = .002). The 5-year overall survival rate and 5-year disease-free survival rate of the group receiving rAd-p53 combined with RT were 7.5% (P = .34) and 11.7% (P = .21) higher than those of the group receiving RT alone. No dose-limiting toxicity or adverse events appeared, except for transient fever after rAd-p53 administration.
In patients with NPC, rAd-p53 was safe and biologically active. Our results indicated that rAd-p53 improves radiotherapeutic tumor control and survival rate in patients with NPC.
|资助机构||National Science Committee|
|作者单位||1.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Radiotherapy, Beijing 100036, Peoples R China|
2.Fujian Prov Canc Hosp, Fuzhou, Peoples R China
|Pan, Jian-ji,Zhang, Shan-wen,Chen, Chuan-beng,et al. Effect of Recombinant Adenovirus-p53 Combined With Radiotherapy on Long-Term Prognosis of Advanced Nasopharyngeal Carcinoma[J]. JOURNAL OF CLINICAL ONCOLOGY,2009,27(5):799-804.|
|APA||Pan, Jian-ji.,Zhang, Shan-wen.,Chen, Chuan-beng.,Xiao, Shao-wen.,Sun, Yan.,...&Lu, You-yong.(2009).Effect of Recombinant Adenovirus-p53 Combined With Radiotherapy on Long-Term Prognosis of Advanced Nasopharyngeal Carcinoma.JOURNAL OF CLINICAL ONCOLOGY,27(5),799-804.|
|MLA||Pan, Jian-ji,et al."Effect of Recombinant Adenovirus-p53 Combined With Radiotherapy on Long-Term Prognosis of Advanced Nasopharyngeal Carcinoma".JOURNAL OF CLINICAL ONCOLOGY 27.5(2009):799-804.|